Celldex Therapeutics, Inc. (CLDX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.83-0.16 (-4.14%)
As of 2:15 PM EDT. Market open.
People also watch:
ACADCLVSARRYSGENSRPT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open4.00
Prev Close3.99
Bid3.82 x 4600
Ask3.83 x 2600
Day's Range3.82 - 4.01
52wk Range2.96 - 18.62
1y Target EstN/A
Market Cap384.59M
P/E Ratio (ttm)-2.88
Beta2.63
Volume1,488,987
Avg Vol (3m)2,065,296
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : September 29, 2016
    Capital Cube4 hours ago

    Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : September 29, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Celldex Therapeutics, Inc. a score of 28. Our analysis is based on comparing Celldex Therapeutics, Inc. with the following peers – Seattle Genetics, Inc., Northwest Biotherapeutics, Inc., Emergent BioSolutions Inc., Agenus Inc., GlaxoSmithKline plc Sponsored ADR, Amgen Inc., Vical Incorporated, Bristol-Myers Squibb Company, Pfizer Inc. and CytRx ... Read more (Read more...)

  • Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 28, 2016
    Capital Cubeyesterday

    Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 28, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Celldex Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Why Celldex Therapeutics, Inc. Ran Higher Today
    Motley Fool2 days ago

    Why Celldex Therapeutics, Inc. Ran Higher Today

    Investors await clinical trial data.